Jeffrey E. Lancet
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
2014/04/01 by Jeffrey E. Lancet, Jorge E. Cortes, Jörge E. Cortes +13 · 26 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Acute Myeloid Leukemia Research #Histone Deacetylase Inhibitors Research #Advanced biosensing and bioanalysis techniques